Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the pricing of the previously announced public offering of the Company’s preferred stock. ARCA will issue to investors an aggregate of approximately 125,000 shares of Series A Convertible Preferred Stock together with warrants to purchase approximately 6.25 million shares of common stock. Each share of Series A preferred stock is convertible into 100 shares of common stock. Each investor will receive a warrant to purchase 50 shares of common stock for each share of preferred stock purchased. ARCA expects to receive approximately $18 million in net proceeds from the stock offering. Dawson James Securities, Inc. acted as sole placement agent for the offering.
Help employers find you! Check out all the jobs and post your resume.
